FindTrial
Sign In

BIBW2992

DRUG5 trials

Sponsors

Boehringer Ingelheim, Yonsei University, BioGene Pharmaceutical Ltd.

Conditions

Carcinoma, Non-Small-Cell LungEndometriosisEndometriosis ExternaEndometriosis OvaryEndometriosis, RectumGlioblastomaNeoplasmsSquamous Cell Carcinoma of Esophagus

Phase 1

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours
CompletedNCT00809133
Boehringer IngelheimNeoplasms
Start: 2007-05-31End: 2015-02-28Updated: 2016-03-14
Open Label Trial to Explore Safety of Combining Afatinib (BIBW 2992) and Radiotherapy With or Without Temozolomide in Newly Diagnosed Glioblastoma Multiform
CompletedNCT00977431
Boehringer IngelheimGlioblastoma
Start: 2009-09-17End: 2017-09-12Updated: 2019-02-18
Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis
WithdrawnNCT03481842
BioGene Pharmaceutical Ltd.Endometriosis, Endometriosis Externa, Endometriosis Ovary +1
Start: 2021-10-10End: 2021-10-10Updated: 2021-10-29

Phase 2

Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients
CompletedNCT00730925
Boehringer IngelheimCarcinoma, Non-Small-Cell Lung
Start: 2008-06-30Updated: 2014-03-26
A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus
NCT02353936
Yonsei UniversitySquamous Cell Carcinoma of Esophagus
Start: 2015-01-31End: 2020-01-31Updated: 2019-02-11

Related Papers

Afatinib and radiotherapy, with or without temozolomide, in patients with newly diagnosed glioblastoma: results of a phase I trial.
2021-11-1713 citations
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors.
2018-08-073 citations
Phase I study of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in newly diagnosed glioblastoma (GB).
Journal of Clinical Oncology2018-05-20
Phase II study of afatinib in recurrent and/or metastatic esophageal squamous cell carcinoma (R/M ESCC) (KCSG HN14-18).
Journal of Clinical Oncology2017-05-20
A phase I study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients (pts) with advanced solid tumors.
Journal of Clinical Oncology2016-05-20
A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
2015-08-1823 citations